Highlights on endoglin (CD105): From basic findings towards clinical applications in human cancer

被引：132
作者：
Fonsatti E. [1 ]
Maio M. [1 ,2 ]
机构：
[1] Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico
[2] Div. of Med. Oncology/Immunotherapy, Department of Oncology, University Hospital of Siena
来源：
Journal of Translational Medicine | / 2卷 / 1期
关键词：
CD105; Human Umbilical Vein Endothelial Cell; Hereditary Hemorrhagic Telangiectasia; CD105 Promoter; Vascular Target;
D O I：
10.1186/1479-5876-2-18
中图分类号：
学科分类号：
摘要：
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting (s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed. © 2004 Fonsatti and Maio; licensee BioMed Central Ltd.
引用
收藏
页数：7
相关论文
共 85 条
[21]  
Chung Y.C., Hou Y.C., Pan A.C., Endoglin (CD105) expression in the development of haemorrhoids, Eur. J. Clin. Invest., 34, pp. 107-112, (2004)
[22]  
Fonsatti E., Del Vecchio L., Altomonte M., Sigalotti L., Nicotra M.R., Coral S., Natali P.G., Maio M., Endoglin: An accessory component of the TGF-beta- binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies, J. Cell Physiol., 188, pp. 1-7, (2001)
[23]  
Fonsatti E., Altomonte M., Nicotra M.R., Natali P.G., Maio M., Endoglin (CD105): A powerful therapeutic target on tumor-associated angiogenetic blood vessels, Oncogene, 22, pp. 6557-6563, (2003)
[24]  
Wang J.M., Kumar S., Pye D., Haboubi N., Al-Nakib L., Breast carcinoma: Comparative study of tumor vasculature using two endothelial cell markers, J. Natl. Cancer Inst., 86, pp. 386-388, (1994)
[25]  
Wikstrom P., Lissbrant I.F., Stattin P., Egevad L., Bergh A., Endoglin [CD105] is expressed on immature blood vessels and is a marker for survival in prostate cancer, Prostate, 51, pp. 268-275, (2002)
[26]  
Yu J.X., Zhang X.T., Liao Y.Q., Zhang Q.Y., Chen H., Lin M., Kumar S., Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance, World J. Gastroenterol., 9, pp. 2866-2869, (2003)
[27]  
Cheifetz S., Bellon T., Cales C., Vera S., Bernabeu C., Massague J., Letarte M., Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells, J. Biol. Chem., 267, pp. 19027-19030, (1992)
[28]  
Lastres P., Letamendia A., Zhang H., Rius C., Almendro N., Raab U., Lopez L.A., Langa C., Fabra A., Letarte M., Bernabe u C., Endoglin modulates cellular response to TGF-β1, J. Cell Biol., 133, pp. 1109-1121, (1996)
[29]  
Barbara N.P., Wrana J.L., Letarte M., Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily, J. Biol. Chem., 274, pp. 584-594, (1999)
[30]  
Govinden R., Bhoola K.D., Genealogy, expression, and cellular function of transforming growth factor-beta, Pharmacol. Ther., 98, pp. 257-265, (2003)
123456789